Technology developed by Nanobiosym, founded by Anita Goel, to enable personalized diagnostic testing won the Grand Prize of the Nokia Sensing XCHALLENGE in 2013, and this month was awarded the top prize in the Galactic Grant Competition.
Archive for the 'Health & longevity' Category
The SENS Research Foundation is once again hosting its Rejuvenation Biotechnology Conference here in Silicon Valley: August 19-21, Hyatt Regency San Francisco Airport in Burlingame CA. Register before July 15 to take advantage of early bird pricing.
Foresight friends can use this discount to attend the SENS Rejuvenation Biotechnology Conference August 21-23, 2014 Santa Clara, California.
The photos from the 2014 Foresight Technical Conference highlight entrepreneurial efforts in space, biotechnology, and life extension.
RNA interference provides potential cures for various diseases by silencing the expression of specific genes in specific organs, but delivering the RNA molecules to the right place is very difficult. A novel nanoparticle provides unprecedented efficiency in silencing target genes in liver cells.
The concern of the US GAO for a gap in nanomanufacturing is well-placed, but it is only half of the problem with the limited US vision of the impact of nanotechnology on the future world economy.
A reconstituted high-density lipoprotein nanoparticle reduces inflammation in advanced atherosclerotic plaques in mice. Will it work in humans to prevent repeat heart attacks and stroke?
A new book by Frank Boehm explores the challenges, possibilities, and visions of nanomedical device and systems design.
Gold nanoparticles densely coated with RNA molecules intended to silence a gene essential for an incurable brain cancer proved effective in mice engrafted with human glioblastoma multiforme tumor.
Doug Wolens’s documentary “THE SINGULARITY: Will we survive our technology” premieres at San Francisco’s Castro Theatre September 16, 2013.
In a 47-minute interview Christine Peterson discusses the future that science and technology is bringing over the next few decades, and how to get involved to push the future in a positive direction.
An interview with Foresight Co-Founder and Past President Christine Peterson covering both the current state and the future prospects of nanotechnology is available on Youtube.
Optimizing the size and charge of nanoparticles engineered from polymers delivers drugs directly to mitochondria, effectively treating cells with drugs for a variety of diseases.
Studies in mice with otherwise fatal blood clots have shown that targeting a clot-busting drug to regions where blood flow is blocked restores circulation and increases survival with a much lower, safer dose of the drug.
A new nanomaterial provides a three million-fold improvement in the sensitivity of common medical tests, potentially permitting earlier detection of cancer and Alzheimer’s disease.
Nancy K Mize, PhD, Scientist, Innovator, and CEO of GENOGEN Inc., will continue Foresight’s local Bay Area community events with a lecture “GENOGEN: Regenerating Skin for Life”. GENOGEN is developing products that activate resident skin stem cells to stimulate local areas of regeneration of skin naturally – the way children heal.
Nanoparticles targeted to cancer cells by antibodies cannot achieve enough specificity to kill drug-resistant cancer cells while sparing normal cells, but can achieve enough specificity to produce nanobubbles only in cancer cells, so the drug only enters cancer cells.
Gold nanostars targeted to a protein over-expressed in most cancer cells are shuttled by that protein directly to the cancer cell nucleus where illumination with a laser light releases a drug that deforms the nucleus and kills the cell.
Clinical trials in patients with advanced or metastatic tumors using targeted nanoparticles to deliver a standard chemotherapeutic drug showed tumor shrinkage, even in the case of cancers for which that drug is not normally effective.
In a rat model of ischemic damage, nanoparticle delivery of a growth factor and a coreceptor promotes regrowth of damaged blood vessels in seven days.